Alexandria Real Estate Equities, Inc.

NYSE:ARE Stock Report

Market Cap: US$10.1b

Alexandria Real Estate Equities Valuation

Is ARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$111.24
Fair Value
47.7% undervalued intrinsic discount
13
Number of Analysts

Below Fair Value: ARE ($58.22) is trading below our estimate of fair value ($111.24)

Significantly Below Fair Value: ARE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARE?

Key metric: As ARE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ARE. This is calculated by dividing ARE's market cap by their current revenue.
What is ARE's PS Ratio?
PS Ratio3.3x
SalesUS$3.06b
Market CapUS$10.06b

Price to Sales Ratio vs Peers

How does ARE's PS Ratio compare to its peers?

The above table shows the PS ratio for ARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
OHI Omega Healthcare Investors
10.8x0.77%US$12.9b
DOC Healthpeak Properties
4.5x3.61%US$12.7b
AHR American Healthcare REIT
3.6x8.40%US$7.7b
HR Healthcare Realty Trust
5.2x-0.68%US$6.3b
ARE Alexandria Real Estate Equities
3.3x0.72%US$10.1b

Price-To-Sales vs Peers: ARE is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (5.8x).

Price to Sales Ratio vs Industry

How does ARE's PS Ratio compare vs other companies in the US Health Care REITs Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
DHC Diversified Healthcare Trust
0.7x2.34%US$1.03b
HLTC National Healthcare Properties
0.6xn/aUS$218.14m
GBCS Selectis Health
0.2xn/aUS$6.75m
No more companies available in this PS range
ARE 3.3xIndustry Avg. 4.8xNo. of Companies3PS02.85.68.411.214+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ARE is good value based on its Price-To-Sales Ratio (3.3x) compared to the US Health Care REITs industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is ARE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio4.7x

Price-To-Sales vs Fair Ratio: ARE is good value based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ARE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$58.22
US$84.00
+44.28%
23.34%US$130.00US$52.00n/a13
Oct ’26US$83.46
US$96.79
+15.97%
19.40%US$144.00US$71.00n/a14
Sep ’26US$82.44
US$96.42
+16.95%
20.63%US$144.00US$71.00n/a12
Aug ’26US$76.01
US$98.83
+30.03%
20.11%US$144.00US$71.00n/a12
Jul ’26US$74.49
US$97.31
+30.63%
20.65%US$144.00US$74.00n/a13
Jun ’26US$70.19
US$104.46
+48.83%
20.06%US$144.00US$76.00n/a13
May ’26US$73.42
US$109.08
+48.57%
18.04%US$144.00US$76.00n/a13
Apr ’26US$91.15
US$116.54
+27.85%
9.91%US$144.00US$100.00n/a13
Mar ’26US$102.26
US$118.25
+15.64%
9.28%US$144.00US$104.00n/a12
Feb ’26US$97.35
US$119.25
+22.50%
8.75%US$144.00US$104.00n/a12
Jan ’26US$97.55
US$120.15
+23.17%
8.48%US$144.00US$105.00n/a13
Dec ’25US$110.23
US$128.15
+16.26%
14.30%US$186.00US$112.00n/a13
Nov ’25US$110.86
US$133.08
+20.04%
12.98%US$186.00US$114.00US$58.2213
Oct ’25US$117.11
US$136.46
+16.52%
11.22%US$186.00US$125.00US$83.4613
Sep ’25US$119.57
US$137.62
+15.09%
11.49%US$186.00US$126.00US$82.4413
Aug ’25US$115.02
US$139.77
+21.52%
10.96%US$186.00US$126.00US$76.0113
Jul ’25US$115.81
US$142.77
+23.28%
10.08%US$186.00US$127.00US$74.4913
Jun ’25US$119.00
US$142.77
+19.97%
10.08%US$186.00US$127.00US$70.1913
May ’25US$116.79
US$143.08
+22.51%
9.97%US$186.00US$127.00US$73.4213
Apr ’25US$125.50
US$141.00
+12.35%
10.94%US$186.00US$118.00US$91.1513
Mar ’25US$124.27
US$140.92
+13.40%
10.96%US$186.00US$118.00US$102.2613
Feb ’25US$122.47
US$142.08
+16.01%
10.68%US$186.00US$118.00US$97.3513
Jan ’25US$126.77
US$135.67
+7.02%
13.94%US$186.00US$108.00US$97.5512
Dec ’24US$118.14
US$131.58
+11.38%
15.04%US$186.00US$108.00US$110.2312
Nov ’24US$92.90
US$136.50
+46.93%
15.85%US$186.00US$108.00US$110.8612
US$84
Fair Value
30.7% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/02 00:43
End of Day Share Price 2025/10/31 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alexandria Real Estate Equities, Inc. is covered by 32 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wesley GolladayBaird
David RodgersBaird
Ross SmotrichBarclays